Monkasta (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway cells. By preventing leukotriene D4 from binding, it stops the cascade that causes bronchoconstriction, mucus production, vascular leakage and recruitment of inflammatory cells, thereby reducing airway narrowing and allergic inflammation.

The dosage of Monkasta is individualized by the prescribing healthcare professional based on the patient’s age, weight, severity of disease and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dose and schedule.

Safety data for montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit outweighs any risk. Caution is also advised during breastfeeding, and the prescriber should evaluate infant exposure.

To request Monkasta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monkasta (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients who prefer oral therapy or need additional control of allergic components, but it is generally used as add‑on therapy rather than a sole replacement for inhaled steroids.

Monkasta tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Monkasta is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or sublingual use.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, liver enzyme elevations indicating possible hepatic injury, neuropsychiatric effects like depression or suicidal thoughts, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these occur.

Monkasta is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, active psychiatric disorders, or those taking strong CYP3A4 inducers that may diminish therapeutic effect.